Vesugen Peptide

Vesugen Molecular Structure & Chemical Properties

Vesugen represents a pioneering tripeptide bioregulator in the field of vascular aging research, first identified and synthesized by Russian scientist Vladimir Khavinson in the 1990s. Derived from a specific amino acid sequence associated with vascular wall proteins, this short-chain peptide has garnered significant attention for its potential epigenetic regulatory mechanisms and tissue-specific effects on vascular endothelial cells. Unlike many larger peptide compounds that face bioavailability challenges, Vesugen’s compact three-amino-acid structure enables cellular transport via proton-coupled oligopeptide transporters (POT family) and L-type amino acid transporters (LAT), allowing it to reach target tissues and interact with DNA regulatory regions.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure features lysine at the N-terminus (providing a positive charge), followed by glutamic acid and aspartic acid residues (both acidic amino acids), creating a tripeptide with both charged and polar characteristics that facilitate cellular uptake and DNA interaction.

Vesugen Mechanism of Action

Vesugen exerts its biological effects primarily through epigenetic regulation of gene expression rather than traditional receptor-mediated signaling. Current research suggests that the peptide’s mechanism involves direct interaction with DNA promoter regions, particularly targeting genes associated with vascular endothelial cell proliferation, differentiation, and aging-related processes. This epigenetic approach distinguishes Vesugen from conventional pharmacological agents by influencing fundamental cellular processes at the transcriptional level.

Primary Molecular Mechanisms

Ki-67 Gene Regulation – Cell Proliferation Control

Research demonstrates that Vesugen significantly upregulates expression of Ki-67, a nuclear protein marker closely associated with cellular proliferation[1]. Molecular docking studies revealed that Vesugen interacts specifically with the promoter region of the MKI67 gene through binding to the minor groove of DNA[1]. Key findings include:

• Direct interaction with core promoter sequences located from -14 to +12 base pairs relative to transcriptional initiation
• Formation of hydrogen bonds with specific DNA base pairs
• Restoration of Ki-67 expression in aged vascular endothelial cell cultures
• Enhanced proliferative capacity in cells with age-related decline

This mechanism appears particularly relevant in addressing diminished proliferative capacity characteristic of vascular aging, where Ki-67 expression naturally decreases.

SIRT1 Pathway Activation – Metabolic Regulation

Studies indicate that Vesugen peptide influences sirtuin 1 (SIRT1) expression, a NAD-plus-dependent deacetylase protein central to cellular metabolism and longevity[2]. This pathway activation mimics effects associated with calorie restriction:

• Upregulation of SIRT1 protein levels in cellular models
• Enhancement of metabolic processes associated with cellular housekeeping
• Potential improvement in insulin sensitivity through SIRT1 activation
• Modulation of cellular stress response mechanisms

The activation of SIRT1 by Vesugen suggests mechanisms similar to those underlying calorie restriction-induced longevity effects, offering potential geroprotective benefits without dietary intervention.

Gene Expression Modulation – Neuroplasticity and Differentiation

Research in central nervous system models revealed that Vesugen regulates expression of multiple genes critical for neuronal function and aging[3]. Specific gene targets include:

• p16 and p21 – cell cycle regulators and senescence markers
• NES and GAP43 – genes encoding nestin and growth-associated protein 43, involved in neuronal differentiation
• SUMO, APOE, and IGF1 – genes implicated in Alzheimer’s disease pathogenesis and cellular signaling

These findings suggest Vesugen peptide may influence both apoptotic pathways and neurogenesis-related processes through coordinated regulation of multiple genetic targets.

CXCL12 and Transcription Factor Modulation

Investigations in aged fibroblast cultures demonstrated that Vesugen enhances expression of specific chemokines and transcription factors[4]:

• Increased CXCL12 (stromal cell-derived factor 1) expression, associated with immune regulation and angiogenesis
• Upregulation of WEDC1 and other tissue-specific transcription factors
• More pronounced effects observed in aged cell cultures versus young cultures
• Potential restoration of cellular functions that decline with aging

Endothelin-1 Normalization – Vascular Protection

In vitro studies indicated that Vesugen may modulate endothelin-1 expression, a vasoconstrictor typically elevated in atherosclerotic conditions[5]:

• Normalization of endothelin-1 levels in vascular pathology models
• Enhancement of connexin protein expression for improved endothelial integrity
• Potential reduction in vascular stiffness associated with aging
• Support for extracellular matrix stability in blood vessels

Vesugen Peptide Research Applications & Key Findings

Vascular Aging and Endothelial Function Research

Atherosclerosis and Vascular Proliferation

Extensive research in vascular endothelial cell cultures has examined Vesugen’s effects on age-related vascular decline[1]. Key findings include:

• Restoration of proliferative capacity in aged vascular endothelial cells from elderly animal models
• Increased Ki-67 protein synthesis in cells exhibiting age-related proliferation decline
• Normalization of endothelial cell function markers including proliferation-associated proteins
• Reduced presence of polyploid cells associated with vascular lesion development

Molecular docking studies confirmed direct peptide-DNA interactions at the MKI67 gene promoter, providing mechanistic evidence for vasoprotective effects observed in aging models.

Restenosis Prevention Studies

Investigations in vascular injury models demonstrated protective effects against restenosis (blood vessel re-narrowing)[5]:

• Modulation of endothelin-1 expression in atherosclerotic conditions
• Enhanced cellular communication through connexin protein expression
• Potential reduction in smooth muscle cell proliferation contributing to restenosis
• Support for maintaining vascular patency following injury

Central Nervous System Research

Neuroprotective Effects in Alzheimer’s Disease Models

Research in transgenic mouse models of Alzheimer’s disease revealed significant neuroprotective properties[3]. Studies using 5xFAD mice demonstrated:

• Prevention of dendritic spine loss in hippocampal neurons exposed to amyloid toxicity
• Significant increase in mushroom spine density (memory-associated dendritic structures) in male mouse models
• Restoration of neuroplasticity markers impaired in neurodegenerative conditions
• Sex-specific differences in neuroprotective responses

Daily intraperitoneal administration at 400 micrograms per kilogram body weight from 2 to 4 months of age showed tendency toward improved neuroplasticity in disease models.

Hypoxia Protection Research

Studies examined Vesugen’s effects in oxygen deprivation models relevant to stroke and ischemic injury[6]:

• Enhanced anti-oxidative enzyme levels in hypoxic conditions
• Counteraction of neurotoxic reactive oxygen species accumulation
• Potential application in acute ischemic events including stroke
• Neuroprotective effects extending to neonatal hypoxia models

Geroprotective and Anti-Aging Research

Human Clinical Observation Study

A 2015 observational study in 32 adults (aged 41-83 years) with chronic polymorbidity and organic brain syndrome examined geroprotective effects[7]. Findings included:

• Significant anabolic effects improving central nervous system function
• Slowed biological aging rate as measured by cellular and metabolic indicators
• More pronounced geroprotective effect compared to comparator peptide Pinealon
• Enhanced activity of vital organs based on functional assessments

However, the study also noted prooxidant activity via chemiluminescence analysis and decreased CD34-positive hematopoietic stem cells, indicating complex effects requiring further investigation.

Cellular Senescence and Longevity Research

Investigations in aged cell culture models revealed[2]:

• Prevention of age-related decline in cellular function
• Mimicry of calorie restriction effects through SIRT1 pathway activation
• Enhanced cellular survival under stress conditions
• Improved cellular housekeeping functions in aging cells

Cardiovascular Function Studies

Peripheral Vascular Disease Research

Clinical investigation in 41 elderly patients (65-82 years) with lower extremity ischemia evaluated vascular effects[8]:

• Assessment of pain-free walking distance improvements
• Ankle-brachial index measurements reflecting blood flow
• Evaluation of erectile function as vascular health indicator
• Linear blood flow velocity measurements in penile arteries

Results suggested potential improvements in peripheral circulation, though comprehensive data publication remains limited.

Vesugen Pharmacokinetics & Metabolism

Absorption & Distribution

Vesugen’s pharmacokinetic profile benefits from its ultrashort peptide structure, enabling cellular uptake through specialized transport mechanisms rather than requiring traditional receptor-mediated endocytosis[9]. Research on tripeptide transport indicates:

• Transport via POT family carriers (PEPT1, PEPT2, PHT1, PHT2) – proton-coupled oligopeptide transporters that efficiently move di- and tripeptides across cell membranes
• Potential LAT1 and LAT2 transporter involvement for cellular uptake and distribution
• Oral administration route demonstrated in clinical observations, suggesting gastrointestinal absorption via PEPT1 intestinal transporters
• Sublingual administration utilized in some formulations, potentially bypassing first-pass metabolism

Distribution studies remain limited, but the peptide’s small molecular size (390.39 g per mol) and charged residues suggest broad tissue distribution following absorption, with particular accumulation in vascular tissues given its derivation from vascular wall proteins.

Metabolism & Elimination

The metabolic fate of Vesugen follows patterns typical of short-chain bioactive peptides[9]:

• Rapid enzymatic degradation by peptidases in plasma and tissues
• Short plasma half-life characteristic of unmodified tripeptides
• Breakdown into constituent amino acids (lysine, glutamic acid, aspartic acid)
• Potential tissue retention in target cells following cellular uptake

A significant pharmacokinetic consideration involves the disconnect between expected rapid plasma clearance and observed prolonged biological effects extending hours to days after administration, suggesting either intracellular accumulation, persistent epigenetic changes, or active metabolite generation.

Excretion Pathways

Limited published data on Vesugen excretion indicates:

• Likely renal elimination of peptide fragments and amino acid metabolites
• Potential fecal elimination of unabsorbed oral doses
• PEPT2-mediated reabsorption in renal proximal tubules may extend peptide exposure
• No accumulation reported in available studies, consistent with rapid peptide turnover

The lack of comprehensive pharmacokinetic studies represents a significant knowledge gap, particularly regarding tissue-specific distribution, blood-brain barrier penetration (despite CNS effects), and dose-exposure relationships across species.

Vesugen Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse Vesugen doses depending on study design, species, and administration route:

• Mouse models: 400 micrograms per kilogram body weight used in Alzheimer’s disease studies (intraperitoneal injection)
• Human observational studies: 1-2 capsules (typically 200 milligrams per capsule) once or twice daily for 1 month duration
• Cell culture studies: Concentrations ranging from nanomolar to micromolar depending on experimental design
• Clinical observations: Sublingual formulations at 0.1 milligrams total daily dose (divided into 3-4 administrations)

Important: These are experimental doses used in animal studies and observational human protocols and cannot be extrapolated to other species or populations due to significant differences in peptide transport kinetics, tissue distribution, receptor density, metabolic enzyme expression, and pharmacodynamic responses. Peptide pharmacology exhibits substantial species-specific variation that precludes direct dose translation.

Administration Routes in Research

Multiple delivery methods have been investigated:

• Oral (capsule) – Most common in human observational studies; utilizes PEPT1 intestinal transporters for absorption
• Sublingual (drops) – Alternative oral mucosal delivery bypassing first-pass hepatic metabolism
• Intraperitoneal injection – Used in rodent mechanistic studies for reliable systemic delivery
• Cell culture application – Direct addition to culture media for mechanistic investigations

The diversity of administration routes reflects investigation of bioavailability optimization for short-chain peptides vulnerable to enzymatic degradation.

Common Model Organisms and Systems

Vesugen has been studied across multiple experimental models:

• Transgenic mice – 5xFAD Alzheimer’s disease model mice for neurodegeneration research
• Aged animal models – Elderly rats and mice for vascular aging and geroprotection studies
• Primary cell cultures – Vascular endothelial cells, fibroblasts, and neurons from young and aged donors
• Human subjects – Small observational cohorts of elderly adults with polymorbidity and vascular disease

The majority of mechanistic data derives from cell culture and aged animal models, with limited controlled human trial data available in peer-reviewed literature.

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite approximately three decades of investigation originating primarily from Russian research institutions, Vesugen faces substantial limitations that restrict its research utility and prevent broader clinical application.

Lack of Large-Scale Human Clinical Data

The most significant limitation is the minimal published data from rigorous human clinical trials:

• No large-scale, randomized, placebo-controlled trials published in major peer-reviewed journals
• Human data consists primarily of small observational studies and case series
• Safety profile in diverse populations inadequately characterized
• Optimal dosing, treatment duration, and clinical endpoints poorly defined
• Long-term effects (beyond several months) in humans unstudied

Mechanistic Understanding Gaps

Fundamental aspects of Vesugen’s mechanism require clarification:

• Complete catalog of gene targets regulated by Vesugen remains undefined
• Tissue-specific versus systemic effects incompletely characterized
• Hierarchy of epigenetic effects and downstream pathways unclear
• Relative importance of different mechanisms (SIRT1 versus Ki-67 versus others) unresolved
• Potential off-target effects on non-vascular tissues not systematically investigated

Reproducibility and Publication Concerns

Research reproducibility considerations include:

• Majority of published research originated from a single research group and institution
• Limited independent replication of findings by other laboratories
• Minimal data available from Western research institutions
• Standardization of peptide synthesis and purity across studies unclear

Long-Term Safety Considerations

Critical safety questions remain unanswered:

• Chronic administration effects beyond 1-3 months inadequately studied
• Potential for uncontrolled cellular proliferation with long-term Ki-67 upregulation unknown
• Effects on cancer risk or tumor growth in susceptible populations uninvestigated
• Drug interaction potential with common medications uncharacterized
• Prooxidant effects noted in one study require mechanistic explanation and safety assessment

Regulatory & Research Classification Status

Research-Only Status

Vesugen has not received approval from major regulatory authorities for therapeutic use:

• Not approved by the FDA for any medical indication
• Not recognized as Generally Recognized as Safe (GRAS) by FDA
• Available in some countries as dietary supplement but not as pharmaceutical
• Classification varies internationally with limited regulatory oversight in some jurisdictions

The compound’s status as a bioregulator peptide places it in a regulatory gray area in many countries, available for research purposes but lacking the rigorous safety and efficacy evaluation required for therapeutic applications.

Competitive Sport Status

Information regarding World Anti-Doping Agency (WADA) classification of Vesugen is not clearly established in publicly available WADA documentation. Athletes should consult with anti-doping authorities before considering any bioregulatory peptide use.

Research Classification: Vesugen is available primarily for laboratory research use. It is not intended for human consumption, medical treatment, or veterinary applications without appropriate regulatory approval. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Kozlov, K.L., Bolotov, I.I., Linkova, N.S., Drobintseva, A.O., Khavinson, V.K., Dyakonov, M.M., & Kozina, L.S. (2014). Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Advances in Gerontology, 27(4), 646-650. PubMed
   
2. Khavinson, V.K., Tarnovskaia, S.I., Lin’kova, N.S., Guton, E.O., & Elashkina, E.V. (2014). Peptide regulation of aging: results of twelve-year randomized study. Advances in Gerontology, 27(1), 108-114.
3. Khavinson, V., Ilina, A., Kraskovskaya, N., Linkova, N., Kolchina, N., Mironova, E., Erofeev, A., & Petukhov, M. (2021). Neuroprotective effects of tripeptides-epigenetic regulators in mouse model of Alzheimer’s disease. Pharmaceuticals, 14(6), 515. PubMed
   
4. Khavinson, V.K., Tarnovskaia, S.I., Lin’kova, N.S., Guton, E.O., & Elashkina, E.V. (2014). Short peptides regulate expression of transcription factors during aging. Bulletin of Experimental Biology and Medicine, 156(4), 520-523.
5. Kozlov, K.L., Bolotov, I.I., Linkova, N.S., Drobintseva, A.O., Khavinson, V.K., Dyakonov, M.M., & Kozina, L.S. (2016). Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis. Advances in Gerontology, 29(4), 646-650. PubMed
   
6. Kozina, L.S. (2012). Investigation of antihypoxic properties of short peptides. Advances in Gerontology, 25(3), 474-480.
7. Kozina, L.S., Arutjunyan, A.V., & Khavinson, V.K. (2015). Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Advances in Gerontology, 28(3), 469-475. PubMed
   
8. Kitachev, K.V., Kosheleva, N.A., & Khavinson, V.K. (2014). Clinical efficacy of peptide bioregulator Vesugen in patients with chronic lower extremity ischemia. Advances in Gerontology, 27(2), 341-345.
9. Khavinson, V., Linkova, N., Kozhevnikova, E., Dyatlova, A., & Petukhov, M. (2022). Transport of biologically active ultrashort peptides using POT and LAT carriers. International Journal of Molecular Sciences, 23(14), 7733. PubMed
   

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Vesugen is intended for laboratory research use only.